Referred to the House Committee on Energy and Commerce.
The Grocery Reform And Safety (GRAS) Act would change the Federal Food, Drug, and Cosmetic Act to require that companies notify the Food and Drug Administration (FDA) before treating a substance as "generally recognized as safe" (GRAS) for a new use, provide detailed safety data, and wait for a written FDA "no objection" before using the substance. It creates a public posting and 60-day comment period for GRAS notices, requires FDA to issue determinations within statutory timelines (with one limited extension), and authorizes the agency to object where data are inadequate or experts have conflicts of interest.
Scope and pace of federal oversight: liberals see necessary safety strengthening; conservatives see regulatory overreach and delays.
Relative to its intended legislative type, this bill is a substantive statutory reform that is well-specified and integrated into existing FD&C Act structures.
The Grocery Reform And Safety (GRAS) Act would change the Federal Food, Drug, and Cosmetic Act to require that companies notify the Food and Drug Administration (FDA) before treating a substance as "generally recognized as safe" (GRAS) for a new use, provide detailed safety data, and wait for a written FDA "no objection" before using the substance.
It creates a public posting and 60-day comment period for GRAS notices, requires FDA to issue determinations within statutory timelines (with one limited extension), and authorizes the agency to object where data are inadequate or experts have conflicts of interest.
The bill also requires the FDA to reassess at least 10 specified categories of substances (including previously GRAS substances, color additives, food contact substances, and prior-sanctioned substances) within three years and at least every three years thereafter, with authority to require updated safety evaluations and to revoke prior "no objection" statements if safety concerns arise.
Based solely on the text and usual legislative dynamics, the bill represents a substantial regulatory overhaul of an entrenched GRAS paradigm. Consumer‑safety framing, public comment processes, and fee authority improve its prospects, but significant regulatory burden, probable industry opposition, and the breadth of changes reduce its chance of becoming law without compromise or being folded into a broader legislative vehicle. The absence of sunset provisions and potentially costly reassessments further lowers near‑term prospects.
Relative to its intended legislative type, this bill is a substantive statutory reform that is well-specified and integrated into existing FD&C Act structures. It sets clear procedures for pre-use notification, FDA review timelines, public transparency, periodic reassessments, and funding via appropriations and fee authority.
Scope and pace of federal oversight: liberals see necessary safety strengthening; conservatives see regulatory overreach and delays.
These are examples from the analysis, not a ranked list of the most-affected groups.
Scope and pace of federal oversight: liberals see necessary safety strengthening; conservatives see regulatory overreach and delays.
This persona would likely view the bill as a meaningful strengthening of food-safety oversight and transparency.
They would emphasize that mandatory notification, public posting, and periodic reassessments close longstanding regulatory gaps that allowed some substances to be treated as GRAS without FDA review.
They would welcome the conflict-of-interest provisions, requirements for cumulative- and reproductive-toxicity information, and the agency's ability to revoke prior "no objection" determinations.
A centrist/technocratic persona would generally welcome measures that tighten oversight and increase transparency but would be attentive to practical tradeoffs.
They would appreciate clear timelines, public comment, and codified reassessments, while flagging implementation capacity, potential cost-shifting, and unintended slowdowns in product innovation or supply.
They would look for realistic funding mechanisms, predictable review processes, and measured conflict-of-interest rules.
A mainstream conservative persona would likely view the bill as a substantial expansion of federal regulatory control over food substances and an imposition of new compliance costs.
They would be concerned about pre-notification and the prohibition on using a substance until FDA issues a "no objection" statement, potential delays to product introductions, and cost recovery fees that the private sector must pay.
They would emphasize risks to innovation, small businesses, interstate commerce, and possible unintended market disruptions.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Based solely on the text and usual legislative dynamics, the bill represents a substantial regulatory overhaul of an entrenched GRAS paradigm. Consumer‑safety framing, public comment processes, and fee authority improve its prospects, but significant regulatory burden, probable industry opposition, and the breadth of changes reduce its chance of becoming law without compromise or being folded into a broader legislative vehicle. The absence of sunset provisions and potentially costly reassessments further lowers near‑term prospects.
The bill has not accumulated any surfaced votes yet.
Scope and pace of federal oversight: liberals see necessary safety strengthening; conservatives see regulatory overreach and delays.
Based solely on the text and usual legislative dynamics, the bill represents a substantial regulatory overhaul of an entrenched GRAS paradi…
Relative to its intended legislative type, this bill is a substantive statutory reform that is well-specified and integrated into existing FD&C Act structures. It sets clear procedures for pre-use notification, FDA revi…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.